NCT02435836

A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia

An Open-Label Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 631 (actual)
• Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the study was to determine the safety of aripiprazole administered long-term in doses ranging from 10 to 30 mg per day as a maintenance therapy in subjects with chronic or first episode of schizophrenia. Information on the continued efficacy of aripiprazole was also gathered in this long-term trial (until 31 Dec 2012 or until aripiprazole was otherwise available through marketed means and/or reimbursed).

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Aripiprazole

Timeline

• Start date: 1998-04-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2015-05-06
• Last updated: 2015-09-21
• Results posted: 2015-09-21